uric acid has been researched along with ALS - Amyotrophic Lateral Sclerosis in 36 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (SURE-ALS) trial, inosine raised serum urate and was safe and well-tolerated." | 9.69 | Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis. ( Berry, JD; Beukenhorst, AL; Chan, J; Chase, M; Connolly, M; Cudkowicz, ME; Dagostino, D; Ferment, V; Gelevski, D; Hall, M; Lieberman, C; Locatelli, E; Macklin, EA; Manousakis, G; Nicholson, K; Onnela, JP; Ostrow, J; Paganoni, S; Pothier, L; Randall, R; Schwarzschild, MA; Sherman, AV; Steinhart, E; Walk, D; Walker, DG; Walker, J; Wills, AM; Yu, H, 2023) |
| "Edaravone in amyotrophic lateral sclerosis (ALS) was analyzed in two phase 3 studies (MCI186-16 and MCI186-19)." | 9.51 | Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19. ( Kano, O; Nagano, Y; Nelson, S; Takahashi, F; Ushirogawa, Y; Yoneoka, T, 2022) |
| "Compared to age-matched healthy controls (n = 55), patients with amyotrophic lateral sclerosis (ALS) (n = 26) showed increased oxidative stress as indicated by a significantly increased percentage of oxidized coenzyme Q10 (%CoQ10) in total plasma coenzyme Q10, a significantly decreased level of plasma uric acid, and a significantly decreased percentage of polyunsaturated fatty acids in total plasma free fatty acids (FFA)." | 9.22 | Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. ( Miyazaki, Y; Nagase, M; Yamamoto, Y; Yoshino, H, 2016) |
| "To determine the value of uric acid (UA) as a prognostic biomarker for amyotrophic lateral sclerosis (ALS) using a meta-analysis of hazard ratio-based studies." | 9.12 | The value of serum uric acid as a prognostic biomarker in amyotrophic lateral sclerosis: Evidence from a meta-analysis. ( Furukawa, T; Haji, S; Izumi, Y; Kaji, R; Murakami, N; Osaki, Y; Sako, W, 2021) |
| "To investigate the relationship between serum uric acid (UA) and survival in sporadic amyotrophic lateral sclerosis (sALS) patients." | 8.31 | Gender-specific association of uric acid and survival in sporadic amyotrophic lateral sclerosis patients. ( Bai, J; Feng, F; He, Z; Huang, X; Li, M; Wang, H; Wang, J; Yang, F; Yu, W; Zhang, X, 2023) |
| "Uric acid and edaravone might exert a neuroprotective effect in amyotrophic lateral sclerosis (ALS) by reducing oxidative stress." | 8.12 | Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone. ( Choi, YC; Han, HJ; Kim, SM; Kim, SW; Shin, HY, 2022) |
| "In this study we examined the relationship between urate levels at baseline and functional change measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score after edaravone treatment." | 8.12 | Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19. ( Kano, O; Nagano, Y; Nelson, S; Takahashi, F; Ushirogawa, Y; Yoneoka, T, 2022) |
| "To investigate the association between the serum uric acid (UA) level and amyotrophic lateral sclerosis(ALS)." | 7.83 | [Association of serum uric acid level with amyotrophic lateral sclerosis]. ( Duan, Y; Fan, D, 2016) |
| "Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), currently represent major unmet medical needs." | 6.82 | Inosine in Neurodegenerative Diseases: From the Bench to the Bedside. ( Basile, MS; Bramanti, P; Mazzon, E, 2022) |
| "Uric acid has antioxidant and neuroprotective properties." | 5.91 | [The influence of uric acid on the course of amyotrophic lateral sclerosis]. ( Areprintseva, DK; Kutlubaev, MA; Pervushina, EV, 2023) |
| " In the Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (SURE-ALS) trial, inosine raised serum urate and was safe and well-tolerated." | 5.69 | Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis. ( Berry, JD; Beukenhorst, AL; Chan, J; Chase, M; Connolly, M; Cudkowicz, ME; Dagostino, D; Ferment, V; Gelevski, D; Hall, M; Lieberman, C; Locatelli, E; Macklin, EA; Manousakis, G; Nicholson, K; Onnela, JP; Ostrow, J; Paganoni, S; Pothier, L; Randall, R; Schwarzschild, MA; Sherman, AV; Steinhart, E; Walk, D; Walker, DG; Walker, J; Wills, AM; Yu, H, 2023) |
| "Edaravone in amyotrophic lateral sclerosis (ALS) was analyzed in two phase 3 studies (MCI186-16 and MCI186-19)." | 5.51 | Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19. ( Kano, O; Nagano, Y; Nelson, S; Takahashi, F; Ushirogawa, Y; Yoneoka, T, 2022) |
| "Compared to age-matched healthy controls (n = 55), patients with amyotrophic lateral sclerosis (ALS) (n = 26) showed increased oxidative stress as indicated by a significantly increased percentage of oxidized coenzyme Q10 (%CoQ10) in total plasma coenzyme Q10, a significantly decreased level of plasma uric acid, and a significantly decreased percentage of polyunsaturated fatty acids in total plasma free fatty acids (FFA)." | 5.22 | Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. ( Miyazaki, Y; Nagase, M; Yamamoto, Y; Yoshino, H, 2016) |
| "To determine the value of uric acid (UA) as a prognostic biomarker for amyotrophic lateral sclerosis (ALS) using a meta-analysis of hazard ratio-based studies." | 5.12 | The value of serum uric acid as a prognostic biomarker in amyotrophic lateral sclerosis: Evidence from a meta-analysis. ( Furukawa, T; Haji, S; Izumi, Y; Kaji, R; Murakami, N; Osaki, Y; Sako, W, 2021) |
| "To investigate the relationship between serum uric acid (UA) and survival in sporadic amyotrophic lateral sclerosis (sALS) patients." | 4.31 | Gender-specific association of uric acid and survival in sporadic amyotrophic lateral sclerosis patients. ( Bai, J; Feng, F; He, Z; Huang, X; Li, M; Wang, H; Wang, J; Yang, F; Yu, W; Zhang, X, 2023) |
| "Uric acid and edaravone might exert a neuroprotective effect in amyotrophic lateral sclerosis (ALS) by reducing oxidative stress." | 4.12 | Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone. ( Choi, YC; Han, HJ; Kim, SM; Kim, SW; Shin, HY, 2022) |
| "In this study we examined the relationship between urate levels at baseline and functional change measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score after edaravone treatment." | 4.12 | Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19. ( Kano, O; Nagano, Y; Nelson, S; Takahashi, F; Ushirogawa, Y; Yoneoka, T, 2022) |
| "To investigate the association between the serum uric acid (UA) level and amyotrophic lateral sclerosis(ALS)." | 3.83 | [Association of serum uric acid level with amyotrophic lateral sclerosis]. ( Duan, Y; Fan, D, 2016) |
| "Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), currently represent major unmet medical needs." | 2.82 | Inosine in Neurodegenerative Diseases: From the Bench to the Bedside. ( Basile, MS; Bramanti, P; Mazzon, E, 2022) |
| "Uric acid has antioxidant and neuroprotective properties." | 1.91 | [The influence of uric acid on the course of amyotrophic lateral sclerosis]. ( Areprintseva, DK; Kutlubaev, MA; Pervushina, EV, 2023) |
| "Uric acid is an important natural antioxidant that may reduce oxidative stress." | 1.35 | Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? ( Artamonov, I; Berliner, S; Drory, VE; Ish-Shalom, M; Keizman, D; Maimon, N; Nefussy, B; Tsehori, J; Vered, Y, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (11.11) | 18.7374 |
| 1990's | 2 (5.56) | 18.2507 |
| 2000's | 3 (8.33) | 29.6817 |
| 2010's | 16 (44.44) | 24.3611 |
| 2020's | 11 (30.56) | 2.80 |
| Authors | Studies |
|---|---|
| Han, HJ | 1 |
| Shin, HY | 1 |
| Choi, YC | 1 |
| Kim, SM | 1 |
| Kim, SW | 1 |
| Basile, MS | 1 |
| Bramanti, P | 1 |
| Mazzon, E | 1 |
| Takahashi, F | 2 |
| Kano, O | 2 |
| Nagano, Y | 2 |
| Yoneoka, T | 2 |
| Nelson, S | 2 |
| Ushirogawa, Y | 2 |
| Şanlı, BA | 1 |
| Whittaker, KJ | 1 |
| Motsi, GK | 1 |
| Shen, E | 1 |
| Julian, TH | 1 |
| Cooper-Knock, J | 1 |
| Walk, D | 1 |
| Nicholson, K | 2 |
| Locatelli, E | 1 |
| Chan, J | 2 |
| Macklin, EA | 1 |
| Ferment, V | 1 |
| Manousakis, G | 1 |
| Chase, M | 1 |
| Connolly, M | 1 |
| Dagostino, D | 1 |
| Hall, M | 1 |
| Ostrow, J | 1 |
| Pothier, L | 1 |
| Lieberman, C | 1 |
| Gelevski, D | 1 |
| Randall, R | 1 |
| Sherman, AV | 1 |
| Steinhart, E | 1 |
| Walker, DG | 1 |
| Walker, J | 1 |
| Yu, H | 2 |
| Wills, AM | 2 |
| Schwarzschild, MA | 4 |
| Beukenhorst, AL | 1 |
| Onnela, JP | 1 |
| Berry, JD | 1 |
| Cudkowicz, ME | 3 |
| Paganoni, S | 5 |
| Bai, J | 1 |
| Zhang, X | 1 |
| Wang, H | 2 |
| Yu, W | 1 |
| He, Z | 1 |
| Wang, J | 1 |
| Feng, F | 1 |
| Li, M | 1 |
| Yang, F | 1 |
| Huang, X | 1 |
| Kutlubaev, MA | 1 |
| Areprintseva, DK | 1 |
| Pervushina, EV | 1 |
| Zhao, YN | 1 |
| Fu, JY | 1 |
| He, J | 1 |
| Fan, DS | 1 |
| Mitsumoto, H | 2 |
| Garofalo, DC | 1 |
| Santella, RM | 1 |
| Sorenson, EJ | 1 |
| Oskarsson, B | 1 |
| Fernandes, JAM | 1 |
| Andrews, H | 1 |
| Hupf, J | 1 |
| Gilmore, M | 1 |
| Heitzman, D | 1 |
| Bedlack, RS | 1 |
| Katz, JS | 1 |
| Barohn, RJ | 1 |
| Kasarskis, EJ | 1 |
| Lomen-Hoerth, C | 1 |
| Mozaffar, T | 1 |
| Nations, SP | 1 |
| Swenson, AJ | 1 |
| Factor-Litvak, P | 1 |
| Haji, S | 1 |
| Sako, W | 1 |
| Murakami, N | 1 |
| Osaki, Y | 1 |
| Furukawa, T | 1 |
| Izumi, Y | 1 |
| Kaji, R | 1 |
| Shui, A | 1 |
| Schoenfeld, D | 1 |
| Sherman, A | 1 |
| Berry, J | 1 |
| Cudkowicz, M | 1 |
| Atassi, N | 1 |
| O'Reilly, ÉJ | 2 |
| Bjornevik, K | 1 |
| McCullough, ML | 1 |
| Kolonel, LN | 1 |
| Le Marchand, L | 1 |
| Manson, JE | 1 |
| Ascherio, A | 2 |
| Zhang, F | 1 |
| Zhang, Q | 1 |
| Ke, Y | 1 |
| Hao, J | 1 |
| Lu, L | 1 |
| Lu, N | 1 |
| Chen, X | 4 |
| Bakshi, R | 1 |
| Xu, Y | 1 |
| Mueller, KA | 1 |
| Granucci, E | 1 |
| Sadri-Vakili, G | 1 |
| Saito, T | 1 |
| Zhang, C | 1 |
| Yang, Y | 1 |
| Liang, W | 1 |
| Wang, T | 1 |
| Wang, S | 1 |
| Wang, X | 1 |
| Wang, Y | 1 |
| Jiang, H | 1 |
| Feng, H | 1 |
| Wei, QQ | 1 |
| Chen, Y | 1 |
| Cao, B | 2 |
| Ou, R | 2 |
| Hou, Y | 1 |
| Yuan, X | 1 |
| Zhang, L | 1 |
| Liu, H | 1 |
| Shang, H | 2 |
| Zheng, Z | 1 |
| Guo, X | 1 |
| Wei, Q | 1 |
| Song, W | 1 |
| Huang, R | 1 |
| Abraham, A | 1 |
| Drory, VE | 2 |
| Nagase, M | 1 |
| Yamamoto, Y | 2 |
| Miyazaki, Y | 1 |
| Yoshino, H | 1 |
| Duan, Y | 1 |
| Fan, D | 1 |
| Liu, D | 1 |
| Johns, DR | 1 |
| Leitner, M | 1 |
| Keizman, D | 1 |
| Ish-Shalom, M | 1 |
| Berliner, S | 1 |
| Maimon, N | 1 |
| Vered, Y | 1 |
| Artamonov, I | 1 |
| Tsehori, J | 1 |
| Nefussy, B | 1 |
| Ikeda, K | 2 |
| Kawabe, K | 2 |
| Iwasaki, Y | 2 |
| Spasojević, I | 1 |
| Stević, Z | 1 |
| Nikolić-Kokić, A | 1 |
| Jones, DR | 1 |
| Blagojević, D | 1 |
| Spasić, MB | 1 |
| Zoccolella, S | 1 |
| Simone, IL | 1 |
| Capozzo, R | 1 |
| Tortelli, R | 1 |
| Leo, A | 1 |
| D'Errico, E | 1 |
| Logroscino, G | 1 |
| Zhang, M | 1 |
| Quiroz Zárate, A | 1 |
| Jaffa, M | 1 |
| Hirayama, T | 1 |
| Takazawa, T | 1 |
| Sohmiya, M | 1 |
| Tanaka, M | 1 |
| Suzuki, Y | 1 |
| Tanino, Y | 1 |
| Okamoto, K | 1 |
| Liochev, SI | 2 |
| Chen, LL | 2 |
| Hallewell, RA | 2 |
| Fridovich, I | 2 |
| Patten, BM | 1 |
| Mallette, LE | 1 |
| Khondkarian, OA | 1 |
| Larskiĭ, EG | 1 |
| Korshunova, TS | 1 |
| Bunina, TL | 1 |
| Fareed, GC | 1 |
| Tyler, HR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)[NCT03168711] | Phase 2 | 48 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)[NCT02288091] | Phase 1 | 32 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed by the occurrence of adverse events such as kidney stones and gout (expected adverse events) in all participants receiving at least 1 dose of study drug (NCT03168711)
Timeframe: Baseline to Week 24
| Intervention | participants (Number) |
|---|---|
| Inosine | 11 |
| Placebo | 7 |
Tolerance of study drug will be defined as the number of participants who able to complete the 20-week study without permanently discontinuing study drug or suspending study drug for greater than 28 days (NCT03168711)
Timeframe: Baseline to Week 20
| Intervention | Participants (Count of Participants) |
|---|---|
| Inosine | 12 |
| Placebo | 7 |
Safety will be assessed by the occurrence of adverse events. (NCT02288091)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Open-label | 22 |
Tolerability will be defined as the ability of subjects to complete the entire 12-week study on study drug. (NCT02288091)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Open-label | 24 |
Blood samples will be obtained at baseline and after 12 weeks of treatment to measure biomarkers of oxidative stress and damage such as ferric reducing antioxidant power (FRAP). (NCT02288091)
Timeframe: 12 weeks
| Intervention | µM (Mean) | |
|---|---|---|
| Ferric Reducing Antioxidant Power (Baseline) | Ferric Reducing Antioxidant Power (Week 12) | |
| Open-label | 765.7 | 1188.3 |
Blood samples will be obtained at baseline and after 12 weeks of treatment to measure biomarkers of oxidative stress and damage such as glutathione (GSH). (NCT02288091)
Timeframe: 12 weeks
| Intervention | ƥM (Mean) | |
|---|---|---|
| Glutathione at Baseline | Glutathione at Week 12 | |
| Open-label | 94.0 | 84.5 |
Magnetic resonance spectroscopy (MRS) will be performed to measure the levels of glutathione in the motor cortex; levels of glutathione at Week 12 (post-treatment) will be compared to pre-treatment levels. (NCT02288091)
Timeframe: 12 weeks
| Intervention | mM (Mean) | |
|---|---|---|
| Motor Cortex Precentral Gyri (Baseline) | Motor Cortex Precentral Gyri (Week 12) | |
| Open-label | 0.424 | 0.392 |
5 reviews available for uric acid and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Inosine in Neurodegenerative Diseases: From the Bench to the Bedside.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antioxidants; Humans; Inosine; Multiple Sclerosis; | 2022 |
The value of serum uric acid as a prognostic biomarker in amyotrophic lateral sclerosis: Evidence from a meta-analysis.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Humans; Prognosis; Sensitivity and Specificity; Uric Acid | 2021 |
Serum uric acid levels in patients with amyotrophic lateral sclerosis: a meta-analysis.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Case-Control Studies; Cause of Death; Humans; Prognosis; | 2018 |
[A prognostic biomarker in amyotrophic lateral sclerosis].
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Brain; Creatinine; Disease Progression; Electric Impedanc | 2018 |
Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis.
Topics: Amyotrophic Lateral Sclerosis; Female; Humans; Male; Prognosis; PubMed; Sex Factors; Uric Acid | 2014 |
5 trials available for uric acid and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blin | 2022 |
Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Double-Blind Method; Humans; Inosine; Retrospective Studies; Uric Aci | 2023 |
Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration.
Topics: Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Biomarkers; Edaravone; Fatty Acids, Nonesterified; | 2016 |
Serum urate at trial entry and ALS progression in EMPOWER.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Antioxidants; Benzothiazo | 2017 |
The use of isoprinosine in patients with amyotrophic lateral sclerosis.
Topics: Acetamides; Adult; Aged; Amino Alcohols; Amyotrophic Lateral Sclerosis; Benzoates; Clinical Trials a | 1971 |
26 other studies available for uric acid and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone.
Topics: Amyotrophic Lateral Sclerosis; Edaravone; Humans; Oxidative Stress; Uric Acid | 2022 |
Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19.
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Disease Progression; Edaravone; Free Radica | 2022 |
Unbiased metabolome screen links serum urate to risk of Alzheimer's disease.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Genome-Wide Association Study; Humans; Mendelian R | 2022 |
Gender-specific association of uric acid and survival in sporadic amyotrophic lateral sclerosis patients.
Topics: Amyotrophic Lateral Sclerosis; Creatinine; Female; Humans; Male; Uric Acid | 2023 |
[The influence of uric acid on the course of amyotrophic lateral sclerosis].
Topics: Amyotrophic Lateral Sclerosis; Antioxidants; Gout; Humans; Male; Neuroprotection; Uric Acid | 2023 |
[Progress in the application of uric acid-lowering treatments in amyotrophic lateral sclerosis].
Topics: Amyotrophic Lateral Sclerosis; Humans; Uric Acid | 2023 |
Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Biomarkers; Cohort Studies; Creatinin | 2020 |
Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Biomarkers; Databases, Factual; Disease Progression; Fem | 2018 |
Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Case-Control Studies; Cohort Studies; Colorimetry; Female; Huma | 2018 |
Urate mitigates oxidative stress and motor neuron toxicity of astrocytes derived from ALS-linked SOD1
Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Astrocytes; Cell Line; Cells, Cultured; Cultur | 2018 |
Neuroprotection by urate on the mutant hSOD1-related cellular and Drosophila models of amyotrophic lateral sclerosis: Implication for GSH synthesis via activating Akt/GSK3β/Nrf2/GCLC pathways.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Cell Line, Tumor; Disease Models, Animal; Dros | 2019 |
Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Blood Proteins; Case-Control Studies; Cholesterol; Creat | 2019 |
Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; China; Disease Progression; Female; Humans; Male; Middle | 2014 |
[Association of serum uric acid level with amyotrophic lateral sclerosis].
Topics: Amyotrophic Lateral Sclerosis; Blood Urea Nitrogen; Disease Progression; Humans; Logistic Models; Ur | 2016 |
Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress?
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Body Mass Index; Disease Progression; | 2009 |
Do serum uric acid levels reflect oxidative stress in the progression of ALS?
Topics: Aged; Amyotrophic Lateral Sclerosis; Biomarkers; Body Mass Index; Central Nervous System; Creatinine | 2009 |
Different roles of radical scavengers--ascorbate and urate in the cerebrospinal fluid of amyotrophic lateral sclerosis patients.
Topics: Amyotrophic Lateral Sclerosis; Ascorbic Acid; Cerebrospinal Fluid; Electron Spin Resonance Spectrosc | 2010 |
An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Cross-Sectional Studies; Female; Huma | 2011 |
Uric acid levels predict survival in men with amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Female; Humans; Male; Middle Aged; Neuroprotective Agent | 2012 |
Uric acid levels predict survival in men with amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Female; Humans; Male; Middle Aged; Neuroprotective Agent | 2012 |
Uric acid levels predict survival in men with amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Female; Humans; Male; Middle Aged; Neuroprotective Agent | 2012 |
Uric acid levels predict survival in men with amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Female; Humans; Male; Middle Aged; Neuroprotective Agent | 2012 |
Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study.
Topics: Aged; Amyotrophic Lateral Sclerosis; Asian People; Case-Control Studies; Creatinine; Cross-Sectional | 2012 |
An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients.
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Ascorbic Acid; Bilirubin; Case-Contro | 2005 |
Superoxide-dependent peroxidase activity of H48Q: a superoxide dismutase variant associated with familial amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Binding Sites; Cloning, Molecular; Copper; Cytochrome c Group; Escher | 1997 |
The familial amyotrophic lateral sclerosis-associated amino acid substitutions E100G, G93A, and G93R do not influence the rate of inactivation of copper- and zinc-containing superoxide dismutase by H2O2.
Topics: Amyotrophic Lateral Sclerosis; Enzyme Stability; Humans; Hydrogen Peroxide; Kinetics; Metalloprotein | 1998 |
Motor neuron disease: retrospective study of associated abnormalities.
Topics: Adolescent; Adult; Age Factors; Aged; Alkaline Phosphatase; Amyotrophic Lateral Sclerosis; Blood Pre | 1976 |
Medical Grand Rounds from the University of Alabama Medical Center. Lead poisoning.
Topics: Adult; Aged; Alcoholism; Amyotrophic Lateral Sclerosis; Anemia, Macrocytic; Brain Diseases; Diagnosi | 1972 |
[Change in the uric acid content in the blood serum and urine in amyotrophic lateral sclerosis].
Topics: Amyotrophic Lateral Sclerosis; Diet; Humans; Purines; Spectrophotometry; Uric Acid | 1974 |